Pub Date : 2019-01-31DOI: 10.2174/2212697X06666190110120026
V. Gasparyan, H. Harutyunyan, M. V. Mikaelyan, G. Poghosyan
{"title":"Effects of Lysozyme on Ehrlich Ascites Carcinoma Cells: The Possible Physiological Role of Lysozyme in the Prevention of Carcinogenesis","authors":"V. Gasparyan, H. Harutyunyan, M. V. Mikaelyan, G. Poghosyan","doi":"10.2174/2212697X06666190110120026","DOIUrl":"https://doi.org/10.2174/2212697X06666190110120026","url":null,"abstract":"","PeriodicalId":91228,"journal":{"name":"Clinical cancer drugs","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/2212697X06666190110120026","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42087674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-01-31DOI: 10.2174/2212697X06666181220130020
Luigi Manfredi and Gianfranco Natale
: Colorectal cancer (CRC) is the 3 rd most common cause of cancer death worldwide. Regular screening of the asymptomatic population can drastically reduce the mortality rate. CRC screening includes several proceedings although the gold standard remains optical colonoscopy (OC), which is unpleasant, causes pain and discomfort. New technologies exemplified by capsule endoscopy (CE) constitute alternative painless solutions and despite their limitations, e.g. , passive locomotion and absence of on-board instrumentation, are being increasingly used for CRC screening. Research and development centres are investigating novel advanced robotic technologies for diagnostic and therapeutic use. These include wireless communication, active locomotion, sensors, diagnostic, and therapeutic instruments. This review describes the traditional OC procedure and the existing robotic technologies for CRC.
{"title":"New Robotic Technologies in Cancer Colon Screening","authors":"Luigi Manfredi and Gianfranco Natale","doi":"10.2174/2212697X06666181220130020","DOIUrl":"https://doi.org/10.2174/2212697X06666181220130020","url":null,"abstract":": Colorectal cancer (CRC) is the 3 rd most common cause of cancer death worldwide. Regular screening of the asymptomatic population can drastically reduce the mortality rate. CRC screening includes several proceedings although the gold standard remains optical colonoscopy (OC), which is unpleasant, causes pain and discomfort. New technologies exemplified by capsule endoscopy (CE) constitute alternative painless solutions and despite their limitations, e.g. , passive locomotion and absence of on-board instrumentation, are being increasingly used for CRC screening. Research and development centres are investigating novel advanced robotic technologies for diagnostic and therapeutic use. These include wireless communication, active locomotion, sensors, diagnostic, and therapeutic instruments. This review describes the traditional OC procedure and the existing robotic technologies for CRC.","PeriodicalId":91228,"journal":{"name":"Clinical cancer drugs","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/2212697X06666181220130020","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48115844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-01-31DOI: 10.2174/2212697X06666181219095936
Riccardo Presciuttini, R. Danesi, G. Bocci
{"title":"May Endocrine Therapy be Associated with Cognitive Impairment in Breast Cancer Patients?","authors":"Riccardo Presciuttini, R. Danesi, G. Bocci","doi":"10.2174/2212697X06666181219095936","DOIUrl":"https://doi.org/10.2174/2212697X06666181219095936","url":null,"abstract":"","PeriodicalId":91228,"journal":{"name":"Clinical cancer drugs","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/2212697X06666181219095936","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46857952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-01-31DOI: 10.2174/2212697X06666190102105652
S. Kushwaha, Prashant Kumar, A. Rai
Methods: Chitosan/glyceryl monooleate (C/GMO) solution was prepared in 0.33 M citric acid with gentle stirring. The weighed quantity of Drug and Chitosan in the required concentration was stirred with an appropriate quantity of 0.33 M Citric acid for 3 hours. Further, this solution was cooled to 4 o C. Then, to this cooled Chitosan and Drug solution, the desired amount of Glycerol Monooleate was added dropwise with constant stirring to obtain a clear homogenous system. Moreover, it was filtered by membrane filtration using the cellulose membrane. Finally, the prepared pH sensitive formulations were sterilized by autoclaving.
{"title":"Formulation and Evaluation of pH Sensitive Sustained Release Hydrogel of Methotrexate","authors":"S. Kushwaha, Prashant Kumar, A. Rai","doi":"10.2174/2212697X06666190102105652","DOIUrl":"https://doi.org/10.2174/2212697X06666190102105652","url":null,"abstract":"Methods: Chitosan/glyceryl monooleate (C/GMO) solution was prepared in 0.33 M citric acid with gentle stirring. The weighed quantity of Drug and Chitosan in the required concentration was stirred with an appropriate quantity of 0.33 M Citric acid for 3 hours. Further, this solution was cooled to 4 o C. Then, to this cooled Chitosan and Drug solution, the desired amount of Glycerol Monooleate was added dropwise with constant stirring to obtain a clear homogenous system. Moreover, it was filtered by membrane filtration using the cellulose membrane. Finally, the prepared pH sensitive formulations were sterilized by autoclaving.","PeriodicalId":91228,"journal":{"name":"Clinical cancer drugs","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/2212697X06666190102105652","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43750450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-01-31DOI: 10.2174/2212697X06666190102110412
Parijat Pandey and Harish Dureja
{"title":"Erlotinib in Non-Small Cell Lung Cancer: From a thought to Necessity","authors":"Parijat Pandey and Harish Dureja","doi":"10.2174/2212697X06666190102110412","DOIUrl":"https://doi.org/10.2174/2212697X06666190102110412","url":null,"abstract":"","PeriodicalId":91228,"journal":{"name":"Clinical cancer drugs","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/2212697X06666190102110412","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42199854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-05-01DOI: 10.2174/2212697X05666180905094942
Gaurav Sharma, D. Anghore, R. Khare, R. Rawal
{"title":"Oxaliplatin for Colorectal Cancer Therapy: A Review","authors":"Gaurav Sharma, D. Anghore, R. Khare, R. Rawal","doi":"10.2174/2212697X05666180905094942","DOIUrl":"https://doi.org/10.2174/2212697X05666180905094942","url":null,"abstract":"","PeriodicalId":91228,"journal":{"name":"Clinical cancer drugs","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/2212697X05666180905094942","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49132325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-05-01DOI: 10.2174/2212697X0501181101114226
G. Bocci
Dr. Bocci is a professor of Pharmacology at the University of Pisa. He obtained the degree of Medicine (1995), the degree of Clinical Pharmacology (1999) and a PhD in Pharmacology (2003) from the University of Pisa. Dr. Bocci was post-doctoral fellow for 3 years at the University of Toronto. Dr. Bocci is PI of projects granted by international associations, foundations and pharmaceutical companies. He is member of ASCO and AACR. He is author of more than 130 scientific papers published on international journals, 11 chapters on books, and 5 patents. He is regional editor of Clinical Cancer Drugs from the foundation of the journal.
{"title":"Meet Our Regional Editor","authors":"G. Bocci","doi":"10.2174/2212697X0501181101114226","DOIUrl":"https://doi.org/10.2174/2212697X0501181101114226","url":null,"abstract":"Dr. Bocci is a professor of Pharmacology at the University of Pisa. He obtained the degree of Medicine (1995), the degree of Clinical Pharmacology (1999) and a PhD in Pharmacology (2003) from the University of Pisa. Dr. Bocci was post-doctoral fellow for 3 years at the University of Toronto. Dr. Bocci is PI of projects granted by international associations, foundations and pharmaceutical companies. He is member of ASCO and AACR. He is author of more than 130 scientific papers published on international journals, 11 chapters on books, and 5 patents. He is regional editor of Clinical Cancer Drugs from the foundation of the journal.","PeriodicalId":91228,"journal":{"name":"Clinical cancer drugs","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48149556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-05-01DOI: 10.2174/2212697X05666180716145923
Roby Will Vencatto, F. Marson, C. Martins, L. Bonadia, C. Lima, C. Bertuzzo
{"title":"Association Between C1236T (rs1128503) Variant in ABCB1 Gene and Breast Cancer Recurrence","authors":"Roby Will Vencatto, F. Marson, C. Martins, L. Bonadia, C. Lima, C. Bertuzzo","doi":"10.2174/2212697X05666180716145923","DOIUrl":"https://doi.org/10.2174/2212697X05666180716145923","url":null,"abstract":"","PeriodicalId":91228,"journal":{"name":"Clinical cancer drugs","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/2212697X05666180716145923","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45149148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-05-01DOI: 10.2174/2212697X05666180706161252
Gonzalo H. Giornelli and Pablo Mando
DOI: 10.2174/2212697X05666180706161252 Abstract: Background: Poly (adenosine diphosphate [ADP]-ribose) polymerase inhibitors have entered into the clinic rapidly and are becoming a powerful therapeutic tool, especially in the management of BRCA associated ovarian cancers. PARP inhibitors have exploited the homologous recombination deficiency, present in up to 50% of ovarian cancers, through synthetic lethality: A novel therapeutic approach to this disease. Objective: Through an extensive review of PARP inhibitors we evaluated the existing evidence in the clinical trial as monotherapy and combined with chemotherapy in ovarian cancer.
{"title":"Currently Approved Poly (Adenosine Diphosphate-Ribose) Inhibitors in Ovarian Cancer: Current Status and Future Directions","authors":"Gonzalo H. Giornelli and Pablo Mando","doi":"10.2174/2212697X05666180706161252","DOIUrl":"https://doi.org/10.2174/2212697X05666180706161252","url":null,"abstract":"DOI: 10.2174/2212697X05666180706161252 Abstract: Background: Poly (adenosine diphosphate [ADP]-ribose) polymerase inhibitors have entered into the clinic rapidly and are becoming a powerful therapeutic tool, especially in the management of BRCA associated ovarian cancers. PARP inhibitors have exploited the homologous recombination deficiency, present in up to 50% of ovarian cancers, through synthetic lethality: A novel therapeutic approach to this disease. Objective: Through an extensive review of PARP inhibitors we evaluated the existing evidence in the clinical trial as monotherapy and combined with chemotherapy in ovarian cancer.","PeriodicalId":91228,"journal":{"name":"Clinical cancer drugs","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/2212697X05666180706161252","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44136225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：